Results Patients and characteristics Forty-four patients diagnosed with treatment-naïve HER2-positive breast cancer (clinical stage IIA-IIIC) were enrolled to receive neoadjuvant TCbIP therapy between November 2021 and November 2023. As of November 2023, a total of 28 patients received six cycles ...